0000899243-22-012782.txt : 20220330
0000899243-22-012782.hdr.sgml : 20220330
20220330160514
ACCESSION NUMBER: 0000899243-22-012782
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220328
FILED AS OF DATE: 20220330
DATE AS OF CHANGE: 20220330
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Peters Richard
CENTRAL INDEX KEY: 0001697628
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37695
FILM NUMBER: 22786405
MAIL ADDRESS:
STREET 1: MERRIMACK PHARMACEUTICALS, INC.
STREET 2: ONE KENDALL SQUARE, SUITE B7201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: YUMANITY THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001445283
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 GUEST STREET
STREET 2: SUITE 4410
CITY: BOSTON
STATE: MA
ZIP: 02135
BUSINESS PHONE: 617-409-5300
MAIL ADDRESS:
STREET 1: 40 GUEST STREET
STREET 2: SUITE 4410
CITY: BOSTON
STATE: MA
ZIP: 02135
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20140813
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS INC
DATE OF NAME CHANGE: 20080916
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-03-28
0
0001445283
YUMANITY THERAPEUTICS, INC.
YMTX
0001697628
Peters Richard
C/O YUMANITY THERAPEUTICS, INC
40 GUEST STREET, SUITE 4410
BOSTON
MA
02135
1
1
0
0
President and CEO
Common Stock
2022-03-28
4
S
0
10715
1.8455
D
115708
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 25, 2022.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
/s/ Richard Peters
2022-03-30